Executive Management Team

Patricia K. Scheller

Chief Executive Officer

Ms. Scheller's commitment to the healthcare industry spans more than 20 years. Prior to joining Prescient Medical, she was the CEO of SomaLogic, a molecular diagnostic company dedicated to developing protein signature arrays. Ms. Scheller also managed several business units at Ortho-Clinical Diagnostics and was director of cardiology systems at Cordis, a Johnson & Johnson company renowned for pioneering vascular disease treatments. There, she was responsible for launching the first PALMAZ-SCHATZ® balloon-expandable Stent in the United States. Ms. Scheller also served in key executive positions at Dade Behring, a clinical diagnostics firm.

Education:

Undergraduate
B.S.E., Biomedical Engineering, Duke University
Executive Business Programs
Harvard Business School
MIT Sloan School of Management
Columbia University
Kellogg School of Management at Northwestern University


Scott C. Durbin

Chief Financial Officer

For over 12 years, Mr. Durbin has focused on corporate finance and strategy for the medical device and pharmaceutical industries. Before joining Prescient Medical, he was a corporate development consultant for Scios Inc., Johnson & Johnson's cardiovascular drug subsidiary. He also served as a financial consultant to Alteon Inc., a company focused on the development of novel therapeutics for heart disease. Prior to consulting, Mr. Durbin spent several years as an investment banker with Lehman Brothers, Inc. His tenure there included the successful execution of over $2 billion in financings and merger related advisory transactions for cardiovascular companies in the medical device and biopharmaceutical industries. Mr. Durbin began his career as a Director of Neurophysiology for Biotronic, Inc.

Education:

Undergraduate
B.S., University of Michigan
Graduate
M.P.H. (Health Management), Yale University School of Medicine and School of Management


Ilana Odess

General Manager, Interventional Cardiology

Ms. Odess has 15 years of healthcare industry experience, with over 10 years in business development and product management, focusing on cardiovascular diseases. Prior to working at Prescient Medical, Ms. Odess was Executive Vice President, Marketing & Sales of Advanced Stent Technologies, Inc., a company that developed bifurcated coronary stents for the treatment of arterial stenosis and restenosis. Ms. Odess successfully executed distribution agreements throughout Asia, Europe, Latin America, Canada, and the Middle East. Previously, Ms. Odess was based in Brussels, Belgium, as Director of Business Development & Marketing EMEA for Cordis Corp., a Johnson & Johnson company. She was responsible for the successful launch of an AAA (Abdominal Aortic Aneurysm) treatment in 24 countries. Ms. Odess has also served as Business Unit Director for Cordis, Israel.

Education:

Undergraduate
B.S., Biochemistry, Bar Ilan University, Israel
Graduate
M.B.A., Bar Ilan University, Israel


Michele V. Frank

General Counsel

Ms. Frank serves as our General Counsel.  She is currently associated with Patton Boggs LLP, which provides Prescient its legal services.  She has worked with early stage medical device companies throughout her legal career, and specializes in the area of intellectual property, including developing and managing intellectual property portfolios.

Education: 

Undergraduate
B.S., Mechanical Engineering, Union College
Graduate
J.D., American University Washington College of Law


James F. Brennan III, Ph.D.

Executive Vice President – Research & Development

Dr. Brennan serves as the Executive Vice President of Research & Development. Dr. Brennan is the author of several seminal works concerning the use of Raman spectroscopy for analyzing human coronary artery and is a recognized expert in optical fibers and devices. He has pioneered several technology platforms and built Intellectual Property portfolios protecting them. Prior to joining PMI, he served as the Vice President of Research & Development for Raydiance, Inc. (Orlando, FL) where he designed and commercialized their femtosecond-duration pulsed laser systems for medical, industrial, and defense applications.  Prior to that, Dr. Brennan worked with several laboratories and institutions, including 3M Company as a chief scientist where he built their Optical Components program from fledgling acquisitions.  He has experience at several additional laboratories including Lincoln Laboratory, Academisch Ziekenhuis (Leiden, Netherlands), and the MIT Harrison Spectroscopy Laboratory.  He is the author of and has published over 60 journal and conference papers, four book chapters, and has been granted 18 patents (several patents pending).

Education

Undergraduate
S.B., Massachusetts Institute of Technology
Graduate
S.M. and E.E., Electrical Engineering Massachusetts Institute of Technology
Ph.D., Physics and Electrical Engineering, Massachusetts Institute of Technology 


Dennis Genito

Vice President, Regulatory and Quality Assurance

Mr. Genito has over 25 years of experience in regulatory affairs.  He was employed by Johnson & Johnson for 14 years.  For the past 7 years Mr. Genito was with the Cordis, a Johnson & Johnson company.  From 1999 until August 2004, as Vice President of Regulatory Affairs, he led the world wide regulatory approval process for the first radiation therapy based catheter system for treating coronary artery disease, the Cypher™ Sirolimus-eluting stent, and an endovascular stent system for treating carotid artery disease.  Mr. Genito was Vice President of Regulatory Affairs for 12 years (1985-1997) at Meadox Medicals (a Boston Scientific company).

Education:

Undergraduate
B.S., University of New Haven
Graduate
M.B.A., Fairleigh Dickenson University